Irisys’ capabilities range from formulation development to commercial manufacturing for various dosage forms including oral liquids, sterile injectables, tablets, topicals, liquid/powder filled capsules
Recro Pharma, a CDMO specialised in complex formulation and manufacturing challenges, has announced the acquisition of Irisys, a San Diego CDMO.
With the acquisition, the company can operate as a full service CDMO, with operations on both the East and West coast of the US. It’s now capable of offering its client base access to services spanning from pre-investigational new drug (IND) development to commercial manufacturing and packaging for various dosage forms.
“Today’s acquisition of IRISYS is truly a transformative transaction for Recro. The joining of these two companies creates an organization that is ideally positioned to achieve Recro’s previously disclosed four-pronged strategy for growth, which includes strengthening the organisation’s leadership and talent, expanding and diversifying our client base, fortifying our financial position, and enhancing our capabilities and competencies,” said David Enloe, President and CEO of Recro.
“Adding the personnel, facilities, capabilities and global customer base of IRISYS advances each of these goals and positions Recro for sustainable, profitable growth moving forward. We welcome the members of the IRISYS team to the Recro family and are eager to begin implementing the integration of the companies.”
Irisys’ capabilities range from formulation development to commercial manufacturing for various dosage forms including oral liquids, sterile injectables, tablets, topicals, liquid/powder filled capsules, ophthalmic droppers, liposomes and nano/microparticles. It serves a global client base within the biopharmaceutical industry with its nearly 40 clients located in six different countries around the world. This includes manufacturing support for four commercial and near-commercial products.
The acquisition will expand Recro’s technical focus to include sterile injectiables, oral liquids, tablets, topicals and other products. It will also give the company capabilities in aseptic fill/finish and lyophilisation. Irisys’ more than three dozen clients, spanning six countries, will also transfer over.